AI Portfolio Summary
In 2025 Q4, Elmind Capital, LP maintained a portfolio of 34 distinct positions. The most significant new addition to the portfolio was COGENT BIOSCIENCES I, which now represents 12.27% of the total fund value.
Total Positions
34
Quarter
2025 Q4
Top Holding
COGT (12.3%)
Top 10 Concentration
68.5%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-34 of 34
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 12.27% | — |
#1
Prev: #—
|
9.5 | 1,170,740 | no change |
NEW
|
1,170,740 | $41,584,685 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SNDX
SYNDAX PHARMACE...
|
Healthcare | 11.50% | — |
#2
Prev: #—
|
9.0 | 1,855,000 | no change |
NEW
|
1,855,000 | $38,973,550 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 7.89% | — |
#3
Prev: #—
|
7.7 | 858,631 | no change |
NEW
|
858,631 | $26,720,597 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 7.21% | — |
#4
Prev: #—
|
6.9 | 482,500 | no change |
NEW
|
482,500 | $24,433,800 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 6.93% | — |
#5
Prev: #—
|
6.8 | 865,000 | no change |
NEW
|
865,000 | $23,493,400 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 6.03% | — |
#6
Prev: #—
|
5.9 | 492,500 | no change |
NEW
|
492,500 | $20,448,600 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BCRX
BIOCRYST PHARMA...
|
Healthcare | 4.95% | — |
#7
Prev: #—
|
5.5 | 2,150,000 | no change |
NEW
|
2,150,000 | $16,770,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 3.97% | — |
#8
Prev: #—
|
5.1 | 291,500 | no change |
NEW
|
291,500 | $13,449,810 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BEAM
BEAM THERAPEUTI...
|
Healthcare | 3.90% | — |
#9
Prev: #—
|
5.1 | 476,338 | no change |
NEW
|
476,338 | $13,204,089 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 3.90% | — |
#10
Prev: #—
|
5.1 | 475,750 | no change |
NEW
|
475,750 | $13,202,063 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KALV
KALVISTA PHARMA...
|
Healthcare | 3.82% | — |
#11
Prev: #—
|
5.0 | 801,300 | no change |
NEW
|
801,300 | $12,940,995 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DVAX
DYNAVAX TECHNOL...
|
Healthcare | 3.09% | — |
#12
Prev: #—
|
4.7 | 679,900 | no change |
NEW
|
679,900 | $10,456,862 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TYRA
TYRA BIOSCIENCE...
|
Healthcare | 2.72% | — |
#13
Prev: #—
|
4.6 | 350,000 | no change |
NEW
|
350,000 | $9,201,500 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NRIX
NURIX THERAPEUT...
|
Healthcare | 2.58% | — |
#14
Prev: #—
|
4.5 | 460,000 | no change |
NEW
|
460,000 | $8,726,200 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
WVE
WAVE LIFE SCIEN...
|
Healthcare | 2.25% | — |
#15
Prev: #—
|
4.4 | 447,846 | no change |
NEW
|
447,846 | $7,613,382 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 1.96% | — |
#16
Prev: #—
|
4.3 | 211,000 | no change |
NEW
|
211,000 | $6,654,940 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KRYS
KRYSTAL BIOTECH...
|
Healthcare | 1.60% | — |
#17
Prev: #—
|
4.1 | 22,000 | no change |
NEW
|
22,000 | $5,423,880 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UTHR
UNITED THERAPEU...
|
Healthcare | 1.58% | — |
#18
Prev: #—
|
4.1 | 11,000 | no change |
NEW
|
11,000 | $5,359,750 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMRN
BIOMARIN PHARMA...
|
Healthcare | 1.44% | — |
#19
Prev: #—
|
4.1 | 82,000 | no change |
NEW
|
82,000 | $4,873,260 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RLAY
RELAY THERAPEUT...
|
Healthcare | 1.34% | — |
#20
Prev: #—
|
4.0 | 536,946 | no change |
NEW
|
536,946 | $4,542,563 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TVTX
TRAVERE THERAPE...
|
Healthcare | 1.24% | — |
#21
Prev: #—
|
4.0 | 110,000 | no change |
NEW
|
110,000 | $4,203,100 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PTGX
PROTAGONIST THE...
|
Healthcare | 0.98% | — |
#22
Prev: #—
|
3.9 | 38,000 | no change |
NEW
|
38,000 | $3,318,920 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGEM
CULLINAN THERAP...
|
Healthcare | 0.95% | — |
#23
Prev: #—
|
3.9 | 310,000 | no change |
NEW
|
310,000 | $3,208,500 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LQDA
LIQUIDIA CORPOR...
|
Healthcare | 0.92% | — |
#24
Prev: #—
|
3.9 | 90,000 | no change |
NEW
|
90,000 | $3,104,100 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CTMX
CYTOMX THERAPEU...
|
Healthcare | 0.88% | — |
#25
Prev: #—
|
3.9 | 700,000 | no change |
NEW
|
700,000 | $2,982,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
URGN
UROGEN PHARMA L...
|
Healthcare | 0.69% | — |
#26
Prev: #—
|
3.8 | 100,000 | no change |
NEW
|
100,000 | $2,342,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMCR
IMMUNOCORE HLDG...
|
Healthcare | 0.60% | — |
#27
Prev: #—
|
3.7 | 58,248 | no change |
NEW
|
58,248 | $2,021,788 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DSGN
DESIGN THERAPEU...
|
Healthcare | 0.58% | — |
#28
Prev: #—
|
3.7 | 207,900 | no change |
NEW
|
207,900 | $1,950,102 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENGN
ENGENE HOLDINGS...
|
Healthcare | 0.56% | — |
#29
Prev: #—
|
3.7 | 210,000 | no change |
NEW
|
210,000 | $1,896,300 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALEC
ALECTOR INC
|
Healthcare | 0.41% | — |
#30
Prev: #—
|
3.7 | 900,000 | no change |
NEW
|
900,000 | $1,404,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 0.40% | — |
#31
Prev: #—
|
3.7 | 112,000 | no change |
NEW
|
112,000 | $1,352,960 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APLS
APELLIS PHARMAC...
|
Healthcare | 0.37% | — |
#32
Prev: #—
|
3.6 | 50,000 | no change |
NEW
|
50,000 | $1,256,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SUPN
SUPERNUS PHARMA...
|
Healthcare | 0.29% | — |
#33
Prev: #—
|
3.6 | 20,000 | no change |
NEW
|
20,000 | $994,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EWTX
EDGEWISE THERAP...
|
Healthcare | 0.22% | — |
#34
Prev: #—
|
3.6 | 30,000 | no change |
NEW
|
30,000 | $744,450 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-34 of 34 holdings